Tell a friend
(Mandatory)
(Mandatory)
(Mandatory)
(Mandatory)

EPF Acknowledgement of financial support 2014

2014 Accounts    
     
Acknowledgement of Financial Support (1)
    % of total income
EPF wishes to thank the European Commission for its support in 2014 in relation to EPF's role in the following projects:    
Renewing Health 3,000.00 € 0.2%
Sustains 23,681.00 € 1.4%
JA PASQ 48,560.40 € 2.9%
JA Chronic Diseases 30,498.60 € 1.8%
Cross Border Health Care Conference 53,355.71 € 3.2%
Empathie 36,062.36 € 2.2%
Interquality 41,566.00 € 2.5%
     
     
EPF wishes to thank the following donors for their support:
     
Operational work programme     
European Commission (Executive Agency for Health and Consumers) 653,966.00 € 39.1%
Baxter World Trade 10,000.00 € 0.6%
GSK 30,000.00 € 1.8%
Janssen 16,500.00 € 1.0%
Merck Sharp & Dohme 30,000.00 € 1.8%
Novartis 30,000.00 € 1.8%
Pfizer 20,000.00 € 1.2%
Sanofi-Aventis 20,000.00 € 1.2%
Note: The donors contribute as follows: European Commission: 80%; industry donors 19,1%; membership fees 0,9%
     
Project portfolio and capacity building programme  
Abbvie 25,000.00 € 1.5%
AMGEN 35,000.00 € 2.1%
Biogen IDEC International GmbH 20,000.00 € 1.2%
CSL Behring Biotherapies 10,000.00 € 0.6%
Gilead 20,000.00 € 1.2%
GSK 50,000.00 € 3.0%
Grünenthal GmbH 10,000.00 € 0.6%
Hoffmann-La Roche 15,000.00 € 0.9%
Hospira Benelux BVBA 25,000.00 € 1.5%
Janssen Pharmaceutica 13,500.00 € 0.8%
Laboratoires Servier 10,000.00 € 0.6%
Novartis  20,000.00 € 1.2%
Pfizer 20,000.00 € 1.2%
S.A. Eli Lilly Benelux N.V 15,000.00 € 0.9%
Sanofi-Aventis 40,000.00 € 2.4%
Shire 5,000.00 € 0.3%
     
The European Patients' Academy on Therapeutic Innovation Public Private Partnership (EUPATI)    
Innovative Medicine Initiative (IMI JU) contribution 171,114.05 € 10.2%
Industry consortium (Hoffman La Roche, Genzyme, Boehringer, VFA, GSK, AMGEN, ESTVE, Novonordis, S.A. Eli Lilly, Novartis, Astra Zeneca, Bayer, UCB, CHIESI, Janssen, Merck) 78,777.00 € 4.7%
     
Note: the income provided represents EPF's share in the consortium's contributions to the project only.
     
Memberships and other income 43,832.21 € 2.6%
     
Total income 1,674,413.33 € 100.0%
     
Accruals and deferrals (1) -80,630.09 €  
     
Total income net of adjustments 1,593,783.24 €  
     
(1) In accordance with generally accepted accounting principles,  funding received in-year is subject to accrual and deferral adjustments proportionate to the level of resources assigned to pluriannual activities and projects. In 2014, this method had the effect of a decrease of total income by € 80.630,09